<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00173459</url>
  </required_header>
  <id_info>
    <org_study_id>9461700671</org_study_id>
    <nct_id>NCT00173459</nct_id>
  </id_info>
  <brief_title>Dynamic Profiles of Cytokine/Chemokine in Severe Acute Respiratory Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel&#xD;
      coronavirus (SARS-CoV). The major clinical features of SARS include fever, dyspnea,&#xD;
      lymphopenia, and a rapid progression of pulmonary infiltrates on chest radiologic images. The&#xD;
      SARS-related deaths have resulted mainly from pulmonary complications, including progressive&#xD;
      respiratory failure due to alveolar damage and acute respiratory distress syndrome (ARDS).&#xD;
      Pathological changes in SARS suggest that SARS sequelae such as infiltration of PMN in lung&#xD;
      tissue, multiple organ dysfunction and ARDS have been associated with cytokines and chemokine&#xD;
      dysregulation. Some patients still manifested lung injury at a time when the viral load was&#xD;
      falling also supports the immune nature of the lung damage. We therefore undertook an&#xD;
      analysis of dynamic production of cytokine/chemokines in SARS patients with an initial normal&#xD;
      chest radiograph in order to improve understanding of disease pathogenesis and improve&#xD;
      patient management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <condition>SARS</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  SARS group: Patients with SARS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospital acquired pneumonia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jung-Yien Chien, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NTUH</affiliation>
  </overall_official>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2005</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

